BACKGROUND: Recently, CD32 has been described to be a specific surface marker of latently HIV-infected CD4 T cells, but little is known about the frequency and distribution of CD32 expression on naive and memory CD8 and CD4 T cell populations in HIV patients and healthy individuals. METHODS: We studied peripheral blood samples of 36 HIV-1-infected patients [23 viremic patients / 13 antiretroviral therapy(ART)-treated] and healthy individuals (n = 14) as well as cells from lymph nodes (8 HIV infected, 5 controls) using a multiparametric flow cytometry panel determining surface expression of CD3, CD8, CD4, CD45RA, CCR7, CD27, CD25, CD127, CCR5, CCR6, CXCR4, CD38, HLA-DR, TIGIT, and PD-1. RESULTS: Overall, expression of CD32 on total peripheral CD4 T cells between viremic HIV patients, ART-treated and healthy individuals only slightly differed (mean values 1.501%, 0.2785%, and 0.2343%, respectively). However, the level of expression was significantly higher in peripheral and lymph nodal memory CD4 T cell subpopulations of viremic patients compared with ART-treated patients and healthy controls. CD32 CD4 T cells showed higher immune activation and higher expression of CXCR4 than their CD32 counterparts. Furthermore, expression of CD32 on total CD4 T cells and memory T cell populations correlated with general immune activation regardless of the infection status. CONCLUSIONS: Follow-up studies will have to further evaluate CD32 as marker of latently HIV-infected CD4 T cells since other host-related variables such as immune activation seem to influence CD32 expression regardless of the infection status.
BACKGROUND: Recently, CD32 has been described to be a specific surface marker of latently HIV-infectedCD4 T cells, but little is known about the frequency and distribution of CD32 expression on naive and memory CD8 and CD4 T cell populations in HIVpatients and healthy individuals. METHODS: We studied peripheral blood samples of 36 HIV-1-infectedpatients [23 viremic patients / 13 antiretroviral therapy(ART)-treated] and healthy individuals (n = 14) as well as cells from lymph nodes (8 HIV infected, 5 controls) using a multiparametric flow cytometry panel determining surface expression of CD3, CD8, CD4, CD45RA, CCR7, CD27, CD25, CD127, CCR5, CCR6, CXCR4, CD38, HLA-DR, TIGIT, and PD-1. RESULTS: Overall, expression of CD32 on total peripheral CD4 T cells between viremic HIVpatients, ART-treated and healthy individuals only slightly differed (mean values 1.501%, 0.2785%, and 0.2343%, respectively). However, the level of expression was significantly higher in peripheral and lymph nodal memoryCD4 T cell subpopulations of viremic patients compared with ART-treated patients and healthy controls. CD32CD4 T cells showed higher immune activation and higher expression of CXCR4 than their CD32 counterparts. Furthermore, expression of CD32 on total CD4 T cells and memory T cell populations correlated with general immune activation regardless of the infection status. CONCLUSIONS: Follow-up studies will have to further evaluate CD32 as marker of latently HIV-infectedCD4 T cells since other host-related variables such as immune activation seem to influence CD32 expression regardless of the infection status.
Authors: Mohamed Abdel-Mohsen; Leticia Kuri-Cervantes; Judith Grau-Exposito; Adam M Spivak; Racheal A Nell; Costin Tomescu; Surya Kumari Vadrevu; Leila B Giron; Carla Serra-Peinado; Meritxell Genescà; Josep Castellví; Guoxin Wu; Perla M Del Rio Estrada; Mauricio González-Navarro; Kenneth Lynn; Colin T King; Sai Vemula; Kara Cox; Yanmin Wan; Qingsheng Li; Karam Mounzer; Jay Kostman; Ian Frank; Mirko Paiardini; Daria Hazuda; Gustavo Reyes-Terán; Douglas Richman; Bonnie Howell; Pablo Tebas; Javier Martinez-Picado; Vicente Planelles; Maria J Buzon; Michael R Betts; Luis J Montaner Journal: Sci Transl Med Date: 2018-04-18 Impact factor: 17.956
Authors: Genevieve E Martin; Matthew Pace; John P Thornhill; Chansavath Phetsouphanh; Jodi Meyerowitz; Morgane Gossez; Helen Brown; Natalia Olejniczak; Julianne Lwanga; Gita Ramjee; Pontiano Kaleebu; Kholoud Porter; Christian B Willberg; Paul Klenerman; Nneka Nwokolo; Julie Fox; Sarah Fidler; John Frater Journal: Front Immunol Date: 2018-05-04 Impact factor: 7.561
Authors: Roger Badia; Ester Ballana; Marc Castellví; Edurne García-Vidal; Maria Pujantell; Bonaventura Clotet; Julia G Prado; Jordi Puig; Miguel A Martínez; Eva Riveira-Muñoz; José A Esté Journal: Nat Commun Date: 2018-07-16 Impact factor: 14.919
Authors: Marcial García; María Angeles Navarrete-Muñoz; José M Ligos; Alfonso Cabello; Clara Restrepo; Juan Carlos López-Bernaldo; Francisco Javier de la Hera; Carlos Barros; María Montoya; Manuel Fernández-Guerrero; Vicente Estrada; Miguel Górgolas; José M Benito; Norma Rallón Journal: Sci Rep Date: 2018-10-19 Impact factor: 4.379